ENXTPA:GNRO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. More Details


Snowflake Analysis

Reasonable growth potential with weak fundamentals.

Share Price & News

How has GeNeuro's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GNRO is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: GNRO's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

6.2%

GNRO

3.0%

FR Biotechs

1.1%

FR Market


1 Year Return

-9.7%

GNRO

35.5%

FR Biotechs

-2.6%

FR Market

Return vs Industry: GNRO underperformed the French Biotechs industry which returned 27.7% over the past year.

Return vs Market: GNRO underperformed the French Market which returned -3% over the past year.


Shareholder returns

GNROIndustryMarket
7 Day6.2%3.0%1.1%
30 Day9.3%12.0%15.2%
90 Day-7.8%22.3%11.6%
1 Year-9.7%-9.7%35.5%35.5%-0.6%-2.6%
3 Year-47.1%-47.1%-31.8%-31.9%16.8%7.1%
5 Yearn/a-63.5%-63.7%48.9%28.7%

Long-Term Price Volatility Vs. Market

How volatile is GeNeuro's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 month ago | Simply Wall St

Our View On GeNeuro's (EPA:GNRO) CEO Pay

5 months ago | Simply Wall St

Is GeNeuro SA's (EPA:GNRO) CEO Pay Fair?

Valuation

Is GeNeuro undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether GeNeuro is trading at an attractive price based on the cash flow it is expected to produce in the future. But as GeNeuro has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is GeNeuro forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

131.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNRO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).

Earnings vs Market: GNRO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GNRO's is expected to become profitable in the next 3 years.

Revenue vs Market: GNRO is forecast to have no revenue next year.

High Growth Revenue: GNRO is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GNRO's Return on Equity is forecast to be very high in 3 years time (103.8%).


Next Steps

Past Performance

How has GeNeuro performed over the past 5 years?

-9.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GNRO is currently unprofitable.

Growing Profit Margin: GNRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GNRO is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.

Accelerating Growth: Unable to compare GNRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GNRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: GNRO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is GeNeuro's financial position?


Financial Position Analysis

Short Term Liabilities: GNRO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: GNRO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: GNRO has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: GNRO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if GNRO has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GNRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is GeNeuro current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GNRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GNRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GNRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GNRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GNRO's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Jesus Martin-Garcia (58 yo)

4.83yrs

Tenure

€735,000

Compensation

Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since...


CEO Compensation Analysis

Compensation vs Market: Jesus's total compensation ($USD875.10K) is above average for companies of similar size in the French market ($USD267.19K).

Compensation vs Earnings: Jesus's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jesus Martin-Garcia
Chairman & CEO4.83yrs€735.00kno data
Miguel Payró
Chief Financial Officer5yrsno datano data
Hervé Perron
Chief Scientific Officerno datano datano data
David Leppert
Chief Medical Officer0.50yrno datano data
Jean-Francois Arrighi
Chief Development Officer0.17yrno datano data

2.7yrs

Average Tenure

58yo

Average Age

Experienced Management: GNRO's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jesus Martin-Garcia
Chairman & CEO4.83yrs€735.00kno data
Michel Dubois
Independent Director12.33yrs€23.10kno data
Gordon Francis
Independent Director5.67yrs€32.30kno data
Giacomo Di Nepi
Independent Director5.33yrs€23.50kno data
Eric Falcand
Independent Director5yrsno datano data
Christophe Guichard
Director5yrsno datano data
Hedi Ben Ibrahim
Director0.17yrno datano data

5.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: GNRO's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.5%.


Top Shareholders

Company Information

GeNeuro SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GeNeuro SA
  • Ticker: GNRO
  • Exchange: ENXTPA
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €59.790m
  • Shares outstanding: 20.48m
  • Website: https://www.geneuro.ch

Number of Employees


Location

  • GeNeuro SA
  • 3 chemin du Pré-Fleuri
  • Plan-les-Ouates
  • Geneva
  • 1228
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNROENXTPA (Euronext Paris)YesClass C Common SharesFREURApr 2016
GEMDB (Deutsche Boerse AG)YesClass C Common SharesDEEURApr 2016
GNROPBATS-CHIXE (BATS 'Chi-X Europe')YesClass C Common SharesGBEURApr 2016
0RHKLSE (London Stock Exchange)YesClass C Common SharesGBEURApr 2016
GNRR.FOTCPK (Pink Sheets LLC)YesClass C Common SharesUSUSDApr 2016

Biography

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, wh...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 19:28
End of Day Share Price2020/11/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.